share_log

Johnson & Johnson | SC 13G: Statement of acquisition of beneficial ownership by individuals-Johnson & Johnson(8.8%),Johnson & Johnson Innovation-JJDC, Inc.(8.8%)

Johnson & Johnson | SC 13G: Statement of acquisition of beneficial ownership by individuals-Johnson & Johnson(8.8%),Johnson & Johnson Innovation-JJDC, Inc.(8.8%)

強生 | SC 13G：超過5%持股股東披露文件-Johnson & Johnson(8.8%),Johnson & Johnson Innovation-JJDC, Inc.(8.8%)
美股SEC公告 ·  07/31 09:11

牛牛AI助理已提取核心訊息

Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation-JJDC, Inc., has filed a Schedule 13G with the Securities and Exchange Commission on July 30, 2024, indicating a significant ownership stake in Rallybio Corporation. The filing reveals that JJDC directly owns 3,636,363 shares of Rallybio's Class A Common Stock, which represents 8.8% of the company's class of securities as of April 10, 2024. This ownership percentage is based on the total number of shares outstanding as reported by Rallybio Corporation. Johnson & Johnson, headquartered in New Jersey, and its Delaware-based subsidiary, JJDC, have stated that the shares were not acquired for the purpose of changing or influencing the control of Rallybio Corporation.
Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation-JJDC, Inc., has filed a Schedule 13G with the Securities and Exchange Commission on July 30, 2024, indicating a significant ownership stake in Rallybio Corporation. The filing reveals that JJDC directly owns 3,636,363 shares of Rallybio's Class A Common Stock, which represents 8.8% of the company's class of securities as of April 10, 2024. This ownership percentage is based on the total number of shares outstanding as reported by Rallybio Corporation. Johnson & Johnson, headquartered in New Jersey, and its Delaware-based subsidiary, JJDC, have stated that the shares were not acquired for the purpose of changing or influencing the control of Rallybio Corporation.
強生公司通過其子公司強生創新-JJDC公司於2024年7月30日向證券交易所提交了13G表格，表明其擁有Rallybio公司的重要股權。此次報告顯示，JJDC直接持有Rallybio公司的A類普通股3636363股，佔公司截至2024年4月10日尚未流通股票總數的8.8%。這一股權百分比基於Rallybio公司報告的流通股總數。總部位於新澤西州的強生公司及其位於特拉華州的子公司JJDC表示，該股份並非爲了改變或影響Rallybio公司的控制權而收購的。
強生公司通過其子公司強生創新-JJDC公司於2024年7月30日向證券交易所提交了13G表格，表明其擁有Rallybio公司的重要股權。此次報告顯示，JJDC直接持有Rallybio公司的A類普通股3636363股，佔公司截至2024年4月10日尚未流通股票總數的8.8%。這一股權百分比基於Rallybio公司報告的流通股總數。總部位於新澤西州的強生公司及其位於特拉華州的子公司JJDC表示，該股份並非爲了改變或影響Rallybio公司的控制權而收購的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間